Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.

Frontiers in microbiology

Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.

Medicine

Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.

Medicines (Basel, Switzerland)

Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.

Cureus

Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.

Cureus

Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.

BMJ open

One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.

Appetite

🚨 $HIMS CHIEF MEDICAL OFFICER, ANANT VINJAMOORI, AT THE FDA PEPTIDES MEETING: "My company [Hims & Hers] intends to offer peptide therapy if allowed. We intend to do so with guardrails because we think that is in the best interest of patients." "We would, in fact, benefit https://t.co/bR3aUJC27D https://t.co/KyMuYsXyDL

I've tested over 100 compounds since 2017 (peptides, shrooms, TRT, nicotine, etc.) to improve my health, performance, and focus. A short list of the ones that made the greatest impact: 1) GLP-1s (the heaviest hitters I've ever used) - Retatrutide - Tirzepatide - Semaglutide

our full reptides peptide tier list: S: - tirzepatide - semaglutide - retatrutide - liraglutide - orforglipron - tesamorelin - hgh - hcg - ghk-cu A: - ss-31 - pt-141 - survodutide - mazdutide - sermorelin - bpc-157 - tb-500 - cjc+ipa - cjc-1295 - ipamorelin - bpc+tb -

🚨 The next bull 🐂 market will be longevity with peptides and $HIMS & $ENHA are at the very forefront of this new market. • The global peptide therapeutics market size is projected to grow from USD 164.0 billion in 2026 to USD 294.6 billion by 2033, at a CAGR of 8.7% from 2026 https://t.co/1JdUEXGX9Q

HANGİ PEPTİT HANGİ AMAÇLA KULLANILIYOR? Retatrutide — obezite ve metabolik hastalık araştırmaları (GLP-1/GIP/Glukagon agonisti) Tirzepatide — kilo kaybı ve tip 2 diyabet araştırmaları Semaglutide — iştah kontrolü ve glukoz metabolizması Cagrilintide — iştah baskılama ve kilo https://t.co/xIQdvyfWVt

The next 2 weeks could be the biggest stretch of 2026 for $HIMS. There are 2 major catalysts investors should be watching and understand. 1) FDA Compounded Peptide Advisory Meeting First, this is not the FDA’s final decision. Here’s how it works: - Independent experts https://t.co/JDEyZ1iIkZ

Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 to the 503A Bulks List for use in compounding for ulcerative colitis. While this is only a recommendation and not a final https://t.co/aqHs90MxkF

🚨 BPC-157 and KPV just received favorable PCAC votes for the 503A Bulk Drug Substances List - 2 of 7 peptides now recommended ✅ Today on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) delivered important non-binding recommendations during day one of https://t.co/iNlQaFx9lH